[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 184
6. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD: Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
  • In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.
  • We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML.
  • Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.
  • CONCLUSIONS: Flavopiridol has anti-AML activity directly and in combination with ara-C and mitoxantrone.
  • This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Cytarabine / administration & dosage. Disease-Free Survival. Female. Flavonoids / administration & dosage. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Piperidines / administration & dosage. Prognosis. Remission Induction. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671131.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


7. Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ: Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant; 2006 Apr;12(4):480-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
  • Primary refractory acute leukemia (AL) has a poor prognosis, although some patients can be salvaged with allogeneic stem cell transplantation (SCT).
  • Induction of complete remission (CR) with conventional chemotherapy before SCT may improve outcome in this patient population.
  • Forty-two patients had acute myelogenous leukemia (AML), 13 patients had acute lymphoblastic leukemia (ALL), and 4 patients had acute biphenotypic leukemia.
  • CR1 rates were similar in AML (54%) and ALL/acute biphenotypic leukemia (67%; P = .52), and analysis of baseline characteristics did not reveal any predictors of response to VP/Cy.
  • In the allogeneic SCT group, 5-year EFS was 52% for AML patients and 14% for ALL patients (P = .04), and only male sex was predictive of a favorable outcome (P = .03).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Leukemia / mortality. Salvage Therapy / mortality. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545732.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D: t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer; 2006 Apr 15;106(8):1730-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
  • BACKGROUND: The t(3;21)(q26;q22) translocation is associated with myeloid leukemias and results in a chimeric oncoprotein containing AML1/RUNX1 variably fused to EAP, MDS1, and/or EVI1.
  • RESULTS: In all 16 patients with chronic myeloproliferative disorders, including 14 with chronic myelogenous leukemia (CML), the occurrence of t(3;21) heralded myeloid blast transformation.
  • Among 10 cases of t(3;21)-associated acute myeloid leukemia, 8 were secondary tumors after chemotherapy for other neoplasms that had been treated with regimens including fludarabine and 5-fluorouracil in 3 patients each and etoposide in 2 patients.
  • The immunophenotype of the blasts in all 22 tested cases was similar, with uniform expression of myeloid markers and CD34 and variable expression of CD7 and CD9, but minimal morphological myeloid maturation.
  • Among the patients with CMPD, 8 died of disease (at a median of 6.5 mos) and 5 achieved disease remission with bone marrow transplantation.
  • Among patients with acute myeloid leukemia/myelodysplastic syndrome, 7 died of disease (at a median of 2 mos) and 2 had persistent leukemia with short follow-up.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 21 / drug effects. Chromosomes, Human, Pair 3 / drug effects. Hydroxyurea / adverse effects. Leukemia, Myeloid / chemically induced. Leukemia, Myeloid / genetics. Lymphocyte Activation / drug effects. Myeloproliferative Disorders / drug therapy. Oncogene Proteins, Fusion / analysis. Translocation, Genetic / drug effects
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Core Binding Factor Alpha 2 Subunit / genetics. DNA-Binding Proteins / genetics. Female. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16532439.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; 0 / Transcription Factors; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


9. Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB: Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma; 2005 Jun;46(6):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
  • The present study evaluated the serum levels of known angiogenic factors and analysed their prognostic significance in patients with acute or chronic leukemia.
  • Enzyme-linked immunosorbent assays (ELISAs) were performed to quantify the basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), tumor necrosis factor-alpha (TNF-alpha), angiogenin, and matrix metalloproteinase-9 (MMP-9) in stored samples obtained before treatment from patients with acute myeloid leukemia (AML; 30 patients), acute lymphoblastic leukemia (ALL; 10 patients), and chronic myelogenous leukemia (CML; 14 patients).
  • The HGF levels were also higher in patients with AML than in healthy individuals, plus there was a significant correlation between the HGF level and the white blood cell count, monocyte count, and serum level of lactate dehydrogenase (LDH) in patients with AML.
  • In a univariate analysis, age and HGF level were both found to be significant parameters predictive for an achievement of complete remission (CR) in patients with AML.
  • The leukemia-free survival (LFS) rate for AML patients with a lower HGF concentration was better than that for AML patients with a higher HGF concentration (1 year LFS rates=75.0% vs. 37.5%, P=0.065).
  • The HGF concentration was an independent prognostic factor for an achievement of CR, plus higher HGF concentrations were associated with a lower survival in patients with AML.
  • [MeSH-major] Hepatocyte Growth Factor / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic. Prognosis. Remission Induction


10. Shima T, Yoshimoto G, Miyamoto T, Yoshida S, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Shimono N, Akashi K: Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia. Transpl Infect Dis; 2009 Feb;11(1):75-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia.
  • Here we report the case of a 43-year-old Japanese woman with acute myelogenous leukemia who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).
  • The patient did not achieve remission despite intensive chemotherapy, and subsequently underwent UCBT with a standard conditioning regimen.
  • [MeSH-major] Bacteremia / microbiology. Cord Blood Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Pulmonary / microbiology
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Fatal Outcome. Female. Humans


11. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant; 2006 Jan;37(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
  • We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT.
  • The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3).
  • The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%).
  • Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs non-CR1: 3 years: 48 vs 89%; P = 0.05).
  • Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and of younger age.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Graft Survival. Humans. Incidence. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous


12. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE: A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood; 2007 Feb 15;109(4):1387-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
  • Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors.
  • In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML.
  • Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%.
  • Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1268-74 [2475589.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2847-53 [1581898.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3229-32 [8205544.001]
  • [Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2318-25 [10873082.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):450-8 [11809695.001]
  • [Cites] Blood. 2002 Jul 1;100(1):29-35 [12070004.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3295-304 [7614464.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5302-9 [7585592.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):708-13 [9044849.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2969-77 [9376577.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1439-45 [9779989.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • (PMID = 17082323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  • [Other-IDs] NLM/ PMC1794070
  •  go-up   go-down


13. Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM: Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma; 2007 Jan;48(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
  • The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described.
  • The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years).
  • We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis


1
Advertisement
4. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res; 2010 Jul;34(7):877-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
  • In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features.
  • Thirty patients (67%) achieved complete remission (CR) and 4 (9%) died.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • [Cites] Cell Death Differ. 2001 Jul;8(7):715-24 [11464216.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]
  • [Cites] Genome Biol. 2001;2(10):RESEARCH0041 [11597333.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3527-38 [12429644.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):307-15 [12538483.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1822-33 [12702569.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Am J Med. 1969 Sep;47(3):351-66 [5258033.001]
  • [Cites] Ann Intern Med. 1975 Jan;82(1):54-7 [16553.001]
  • [Cites] Medicine (Baltimore). 1980 Nov;59(6):409-25 [7003298.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4856-61 [8895733.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):138-48 [16432172.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):697-706 [16690529.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1810-6 [17095617.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73 [17671131.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4052-62 [19144991.001]
  • [CommentIn] Leuk Res. 2010 Jul;34(7):856-7 [20378170.001]
  • (PMID = 19962759.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ NIHMS158765; NLM/ PMC2875369
  •  go-up   go-down


15. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood; 2005 Feb 1;105(3):973-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
  • Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT).
  • All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%).
  • Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%.
  • [MeSH-major] Leukemia / drug therapy. Leukemia / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Myelodysplastic Syndromes / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Reference Values. Treatment Outcome


16. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI: Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet; 2006 Apr;43(4):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients experienced long periods (> or = 1 year) in remission without specific treatment, which is very uncommon in this disease.
  • Two of the six patients harbouring STX11 gene defects developed myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML).
  • These results suggest that STX11 gene mutations may be associated with secondary malignancies (MDS/AML), and that there is segregation of specific clinical features in FHL patients with an underlying genotype.
  • [MeSH-major] Leukemia, Myeloid / genetics. Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / genetics. Mutation. Myelodysplastic Syndromes / genetics. Qa-SNARE Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Genotype. Humans. Infant. Male. Pedigree. Phenotype. Psychomotor Disorders / complications. Psychomotor Disorders / genetics. Remission, Spontaneous


17. Zhang Y, Gu J, Wang M, Ma L, Wang XL, He B, Sun M: [Study on the role of angiogenesis and related factors in leukemias]. Zhonghua Xue Ye Xue Za Zhi; 2005 Mar;26(3):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To observe the bone marrow angiogenesis in leukemia and evaluate the expression and role of endostatin (ES), vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in leukemia patients.
  • The expression of VEGFR in leukemia cells was determined by flow cytometry (FCM).
  • RESULTS: The bone marrow microvessel density (MVD) in 26 cases of acute leukemia (AL) [(20.78 +/- 7.75)/high-power field (HP)] and 5 chronic myelogenous leukemia (CML) [(28.67 +/- 7.32)/HP] at newly diagnosed stage was significantly higher than that in the control group [(9.29 +/- 3.53)/HP, P < 0.01].
  • The bone marrow MVD in the complete remission (CR) groups, (11.33 +/- 5.66)/HP for AL and (17.00 +/- 8.04)/HP for CML, was significantly lower than that of newly diagnosed groups (P < 0.05 and < 0.01).
  • No significant difference was found between the remission groups and the control group (P > 0.05).
  • CONCLUSIONS: Leukemia patients at newly diagnosed stage had remarkable angiogenesis in bone marrow and elevated plasma ES and VEGF concentrations.
  • [MeSH-major] Endostatins / blood. Leukemia / blood. Neovascularization, Pathologic / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow / blood supply. Bone Marrow / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Immunohistochemistry. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Receptors, Vascular Endothelial Growth Factor / metabolism. Young Adult. von Willebrand Factor / metabolism

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946533.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


18. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol; 2005 Oct 1;23(28):7013-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five patients died from acute toxicity.
  • Four patients developed treatment-related myelodysplasia/acute myelogenous leukemia, and three patients died while in remission from MCL.
  • [MeSH-minor] Administration, Oral. Adult. Age Factors. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Feb 1;24(4):724
  • (PMID = 16145068.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


19. Rowe JM: Consolidation therapy: what should be the standard of care? Best Pract Res Clin Haematol; 2008 Mar;21(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adults 18-60 years old with acute myelogenous leukemia (AML) should undergo some form of postremission therapy, however, how much and what kinds of postremission chemotherapy remain unclear.
  • However, the median age of AML patients approaches 70 years; this is a group of patients who often reach minimal disease, but with a median disease-free survival of only 4 to 5 months, regardless of their cytogenetics, and are therefore an ideal patient group for clinical studies.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adolescent. Adult. Age Factors. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Disease-Free Survival. Humans. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342812.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  • [Number-of-references] 17
  •  go-up   go-down


20. Zhang YL, Ren JH, Guo XN, Zhang JN, Wang Y, Qiao SK, Lin FR: [Expression of c-fes gene in leukemia cells and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1429-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-fes gene in leukemia cells and its clinical significance].
  • This study was purposed to investigate the expression of c-fes gene in leukemia patients and its clinical significance.
  • The expression of c-fes mRNA in bone marrow cells from 121 cases of acute and chronic leukemia patients, and the expression of c-fes mRNA in peripheral blood mononuclear cells of 20 normal persons were detected by real time-quantitative reverse transcription polymerase chain reaction (RQ-PCR).
  • The results showed that the level of c-fes mRNA in AML patients was higher than that in normal controls [(48.017 +/- 57.170) x 10(-3) vs (0.152 +/- 0.398) x 10(-3)] (p < 0.0001); but there was no significant differences of level of c-fes mRNA between samples of ALL and normal controls(0.047 +/- 0.068) x 10(-3) vs(0.152 +/- 0.398) x 10(-3) (p>0.05); the level of c-fes mRNA in CML patients was higher than that in normal persons (21.605 +/- 24.818) x 10(-3) vs (0.152 +/- 0.398) x 10(-3) (p < 0.0001).
  • In AML patients, c-fes gene was expressed higher in M(2) (80.77%) and M(3) (92.86%) patients.
  • The remission rate of AML (except M(3))patients who had expression of c-fes gene was 81.08%, which was higher than that of patients with no expression of c-fes gene (40.00%).
  • It is concluded that c-fes gene expression was found in myeloid leukemias, whereas low or no expression in lymphocytic leukemias.
  • All AML (except M(3))patients with high level of c-fes mRNA may get good prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030920.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / FES protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fes
  •  go-up   go-down


21. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Middle Aged. Vincristine / administration & dosage


22. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol; 2008 Nov;143(4):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
  • The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy.
  • Here we report the results of prospective MRD monitoring in 100 adult patients.
  • Ninety-seven patients (97%) achieved complete remission (CR), and the relapse-free survival (RFS) rate was 46% at 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fusion Proteins, bcr-abl / analysis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Piperazines / administration & dosage. Prognosis. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Sep;146(5):576-7 [19555375.001]
  • (PMID = 18986386.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


23. Thomas X, Dombret H: Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology; 2007 Feb;12(1):15-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
  • Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia.
  • Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome.
  • Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Animals. Antimetabolites, Antineoplastic / administration & dosage. Bone Marrow Diseases / chemically induced. Cell Cycle / drug effects. Child. Cytarabine / pharmacology. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Flavonoids / administration & dosage. Flavonoids / pharmacology. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Middle Aged. Piperidines / administration & dosage. Piperidines / pharmacology. Premedication. Prognosis. Rats. Remission Induction / methods. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364988.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 45AD6X575G / alvocidib; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 127
  •  go-up   go-down


24. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, Zawel L, Tran M, Cools J, Gilliland G, Mitsiades C, McMillin DW, Jiang J, Hall-Meyers E, Griffin JD: Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther; 2007 Jul;6(7):1951-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies suggest that these proteins may be a viable target in leukemia because they have been found to be variably expressed in acute leukemias and are associated with chemosensitivity, chemoresistance, disease progression, remission, and patient survival.
  • Another promising therapeutic target, FLT3, is mutated in about one third of acute myelogenous leukemia (AML) patients; promising results have recently been achieved in clinical trials investigating the effects of the protein tyrosine kinase inhibitor PKC412 on AML patients harboring mutations in the FLT3 protein.
  • Of growing concern, however, is the development of drug resistance resulting from the emergence of point mutations in targeted tyrosine kinases used for treatment of acute leukemia patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomimetic Materials / pharmacology. Carrier Proteins. Leukemia / drug therapy. Mitochondrial Proteins. Mutant Proteins / metabolism. Oligopeptides / pharmacology. fms-Like Tyrosine Kinase 3 / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620426.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA36167; United States / NCI NIH HHS / CA / CA66996; United States / NIDDK NIH HHS / DK / DK50654
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Diablo protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / LBW242; 0 / Mitochondrial Proteins; 0 / Mutant Proteins; 0 / Oligopeptides; 120685-11-2 / 4'-N-benzoylstaurosporine; EC 2.7.10.1 / Flt3 protein, mouse; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; H88EPA0A3N / Staurosporine
  •  go-up   go-down


25. Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS: [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):706-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
  • OBJECTIVE: To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial.
  • METHODS: This trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from acute myelogenous leukemia ( AML except M3 type) , acute lymphocytic leukemia ( ALL) , chronic myelogenous leukemia-blast (CML-blast) , totally 155 patients.
  • In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin.
  • The acute myelogenous leukemia regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles.
  • The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
  • The incidence of non-hematological toxicities in domestic idarubicin group and imported idarubicin group was 84.
  • Discontinuation of treatment due to non-hematological toxicity was not neccessary.
  • CONCLUSION: Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia.
  • The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its non-hematological toxicity is tolerable.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Agranulocytosis / chemically induced. Blast Crisis / drug therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Male. Middle Aged. Mucositis / chemically induced. Nausea / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274381.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


26. Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E, Nicolini F, Troncy J, Barraco F, Michallet M, Thomas X: A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. Hematology; 2010 Jun;15(3):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
  • Dose intensity has been demonstrated to be one determinant for treatment efficacy in younger adults with high-risk (relapsed and refractory) acute myelogenous leukemia.
  • Thirty-six patients reached a complete remission, while nine obtained a partial remission.
  • The major non-hematologic toxicities were severe infections but despite this 23 remitters could proceed to their post-remission treatment, although 13 did not because of severe toxicity or early relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / drug therapy. Neutropenia / drug therapy
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Cytarabine / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prognosis. Recombinant Proteins. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20557669.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


27. Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM, Cotelingam JD, Nordberg ML: Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther; 2007;11(4):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: For Philadelphia chromosome positive (Ph+) leukemias (chronic myelogenous leukemia [CML], acute lymphoblastic leukemia [ALL], and rare other leukemias), both allogeneic transplantation and treatment with tyrosine kinase inhibitors offer chances of molecular remission (the molecular marker being consistently undetectable).
  • Molecular remission is defined as a reduction in the quantification of BCR-ABL transcripts to an undetectable level by molecular diagnostic methods, and is considered as a surrogate marker for cure or long-term disease control.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. In Situ Hybridization, Fluorescence / methods. Leukemia / diagnosis. Leukemia / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adult. Aged. Blood Cell Count. Female. Follow-Up Studies. Humans. Leukocytes. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):397-402 [16396761.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):483-91 [16945414.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):29-41 [16426942.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):33-9 [15604889.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3 Suppl 8):22-7 [11526598.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):295-9 [15354415.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):495-502 [16403813.001]
  • [Cites] Br J Haematol. 1998 Jun;101(3):552-7 [9633901.001]
  • [Cites] Leukemia. 2002 Jan;16(1):53-9 [11840263.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3425-32 [15867244.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):243-50 [15347310.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:211-8 [17124063.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):284-9 [12799534.001]
  • [Cites] Eur J Haematol. 2002 May;68(5):272-80 [12144533.001]
  • [Cites] Blood. 2000 Jan 15;95(2):404-8 [10627442.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4701-7 [12576334.001]
  • (PMID = 17705578.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


28. Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor DS, Frangoul HA: Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol Blood Marrow Transplant; 2009 Dec;15(12):1620-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
  • Total body irradiation (TBI)-based conditioning regimens for pediatric patients with acute myelogenous leukemia (AML) beyond first complete remission (CR1) are controversial.
  • We retrospectively evaluated 151 pediatric patients with AML beyond CR1, comparing outcomes in 90 patients who received a TBI-based conditioning regimen and 61 patients who received a Bu-based conditioning regimen.
  • There were no differences between the 2 groups with respect to age, sex, duration of CR1, time from most recent remission to transplantation, or donor source.
  • Our study provides no evidence of an advantage to using TBI in children with AML beyond CR1.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Child. Child, Preschool. Cohort Studies. Cord Blood Stem Cell Transplantation / adverse effects. Cord Blood Stem Cell Transplantation / methods. Disease-Free Survival. Female. Humans. Infant. Male. Multivariate Analysis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Whole-Body Irradiation. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896086.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan
  •  go-up   go-down


29. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • We analyzed the outcome of 31 primary AML patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second remission.
  • Thirty-one AML patients, 20 in first complete remission (FCR), 8 in second complete remission (SCR) and 3 in a partial remission (SPR) were included.
  • All patients showed myeloid engraftment (neutrophils >0.5 x 10(9)/l) after a median of 13 days in FCR group and 15 days in SCR group.
  • Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable remission in primary AML patients transplanted in FCR.
  • A high relapse rate was documented in patients with refractory or relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


30. Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U: Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res; 2009 Sep;33(9):1189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
  • Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy.
  • Assessment of remission and treatment decisions are based on cytological findings.
  • We analyzed the prognostic impact of cytogenetic remission status in 118 patients with abnormal karyotype who received induction chemotherapy.
  • Eighty-three patients achieved complete remission (CR) and 20 achieved partial remission.
  • Median survival (excluding patients with AML M3) of the CCR group was 37 months, as compared to 11 months in patients with persistence of abnormal karyotype (p < 0.0001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Remission Induction
  • [MeSH-minor] Adult. Aged. Female. Humans. Karyotyping. Male. Middle Aged. Prognosis. Translocation, Genetic


36. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia; 2006 Mar;20(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
  • Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive acute leukemias.
  • Thirty-one patients (18 relapsing or refractory Ph+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias) were enrolled.
  • Complete remission (CR) was obtained in 28 out of 30 assessable patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


37. Shen YM, Chao HY, Zhang R, Li WY, Feng YF, Zhu ZL, Xue YQ: [Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia]. Zhonghua Zhong Liu Za Zhi; 2009 May;31(5):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].
  • OBJECTIVE: To explore the prevalence and prognostic significance of JAK2V617F gene mutation in acute myelogenous leukemia M2 (AML-M2) patients.
  • RESULTS: Of 80 de novo AML-M2 patients, 6 at the time of first diagnosis and 1 at relapse were found to have JAK2V617F gene mutation (8.8%, 7/80).
  • Morphologically, the whole blood and bone marrow of the 7 AML-M2 patients with JAK2V617F gene mutation presented a picture of acute leukemia instead of myeloproliferative disorders.
  • Immunophenotypically, bone marrow samples showed myelogenous linage expression.
  • Complete remission was obtained in 4 of 5 AML-M2 patients with JAK2V617F mutation who received treatment, while one patient had no response to the treatment.
  • CONCLUSION: JAK2V617F gene mutation, as a type-1 mutation, might not be an initial event in the pathogenesis of acute myelogenous leukemia, and its presentation does not mean a poor prognosis in de novo AML patients.
  • [MeSH-major] Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799086.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


38. Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ: Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol; 2009 Feb;88(2):159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.
  • Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of adult acute myelogenous leukemia (AML) patients, mainly with a normal karyotype.
  • In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese AML patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.
  • The detection rate of NPM1 mutations in 220 AML patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.
  • Eight patients were followed up after treatment, and five patients in hematologic remission continued to test negative for NPM1 mutations within 2-14 months of follow-up.
  • The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening AML, and for the quantitative analysis of minimal residual diseases.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. China / epidemiology. Female. Follow-Up Studies. Gene Dosage / genetics. Humans. Indicator Dilution Techniques. Male. Middle Aged. Mutation / genetics. Plasmids / genetics. Sensitivity and Specificity


39. Xue SL, Wu DP, Sun AN, Tang XW: CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol; 2008 Feb;83(2):167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
  • Patients with either relapsed or refractory T-cell acute lymphocytic leukemia (T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Achieving complete remission (CR) in these patients is difficult but crucial for the success of allo-HSCT.
  • After initial remission-induction therapy, two patients achieved CR, one showed a partial remission, and all relapsed soon.
  • The CAG regimen (cytosine arabinoside 10 mg/m(2) subcutaneously every 12 hr, day 1-14; aclarubicin 5-7 mg/m(2) intravenously daily, day 1-8; and concurrent use of G-CSF 200 microg/m(2)/day subcutaneously) was devised originally for the treatment of relapsed acute myelogenous leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Aclarubicin / administration & dosage. Adolescent. Adult. Antigens, CD / genetics. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Remission Induction

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874449.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


40. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H: Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res; 2008 Jun 15;14(12):3906-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
  • EXPERIMENTAL DESIGN: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive).
  • Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively.
  • Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Mastocytosis, Systemic / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Dasatinib. Female. Humans. Male. Middle Aged. Philadelphia Chromosome. Remission Induction. Treatment Outcome


41. Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC: Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients. Hematol Oncol; 2007 Jun;25(2):76-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients.
  • To correlate clinical outcomes with the expression of interleukin-2 receptor alpha (CD25) positive cells during induction chemotherapy (IC) in adult patients with acute myeloid leukaemia (AML), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells.
  • Seventy-five patients with newly diagnosed AML received the same initial IC; and serial PB samples were taken.
  • In addition, patients in complete remission (CR) (n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC.
  • [MeSH-major] Interleukin-2 Receptor alpha Subunit / analysis. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD45 / analysis. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 17200986.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


42. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J: Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood; 2009 May 21;113(21):5058-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
  • Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Dasatinib. Female. Humans. Imatinib Mesylate. Leukemia, Myeloid, Accelerated Phase. Male. Middle Aged. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Prognosis. Pyrimidines / administration & dosage. Remission Induction / methods. Survival Analysis. Thiazoles / administration & dosage. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3207-13 [17185463.001]
  • [Cites] Blood. 2007 May 15;109(10):4143-50 [17264298.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3540-6 [17715389.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):111-8 [9576191.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Feb;6(2):113-7 [18347562.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1200-6 [18401416.001]
  • [Cites] Semin Hematol. 2003 Jan;40(1):79-86 [12563614.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1033-41 [12569603.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3097-9 [12842982.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1834-9 [18048643.001]
  • (PMID = 19282457.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC4081366
  •  go-up   go-down


43. Lee SH, Park J, Hwang SK: Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: a case report. J Neurooncol; 2006 Oct;80(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: a case report.
  • Intracranial granulocytic sarcoma (chloroma) may occur rarely in leukemia.
  • A 27-year-old male presented with an isolated recurrence of granulocytic sarcoma manifesting as an intraaxial mass 27 months after complete remission of acute lymphoblastic leukemia.
  • The biopsy result indicated that intraaxial lymphoblastic leukemia infiltration had caused CNS relapse.
  • Although granulocytic sarcoma occurs primarily in patients with acute myelogenous leukemia, the authors report a rare case of intraparenchymal granulocytic sarcoma in acute lymphoblastic leukemia.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Headache / etiology. Humans. Intracranial Hypertension / etiology. Intracranial Hypertension / surgery. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Ventriculoperitoneal Shunt. Vision Disorders / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Radiology. 1986 Jul;160(1):223-5 [3459211.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Acta Haematol. 1998;99(4):231-3 [9644303.001]
  • [Cites] Cancer. 1973 Mar;31(3):520-33 [4511909.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] J Comput Assist Tomogr. 1987 Nov-Dec;11(6):938-41 [3500192.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1592-4 [8883663.001]
  • [Cites] Jpn J Clin Oncol. 1999 Apr;29(4):214-8 [10340046.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):31-5 [12416543.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18(3):663-4 [8879638.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):259-62 [1902023.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):167-80 [9696368.001]
  • [Cites] Clin Neurol Neurosurg. 1986;88(2):135-9 [3463444.001]
  • [Cites] J Comput Assist Tomogr. 1979 Apr;3(2):226-33 [285087.001]
  • [Cites] Neurology. 1982 Jan;32(1):77-80 [6948173.001]
  • (PMID = 16645713.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C: Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res; 2005 Sep 15;11(18):6641-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
  • PURPOSE: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias.
  • Patients achieving a complete remission received up to two additional courses for consolidation.
  • Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete remission, and 1 reversion to chronic-phase chronic myelogenous leukemia.
  • The complete remission rate in a heavily pretreated population was 16% (33% at the highest three dose levels).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / pharmacokinetics. Cell Cycle Proteins / metabolism. Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. HL-60 Cells. Hematopoietic Stem Cell Transplantation. Humans. Immunoblotting. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166443.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proliferating Cell Nuclear Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


45. Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S: Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Biol Blood Marrow Transplant; 2008 Jun;14(6):651-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
  • We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML).
  • At HSCT, 35 patients were in the first or second complete remission (CR1/2), and 15 patients were not in remission (n = 14) or in the third CR (n = 1).
  • The 5-year estimated overall survival (OS) and disease-free survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 82.1% (95% CI, 69.0%-95.2%) in patients with AML in the first or second CR, 46.7% (95% CI, 21.4%-72.0%), and 40.0% (95% CI, 15.3%-64.7%) in patients with AML in other stages.
  • These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for allogeneic HSCT for AML, providing a high DFS and low TRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Cytarabine / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Leukemia, Myelomonocytic, Acute / mortality. Leukemia, Myelomonocytic, Acute / surgery. Male. Middle Aged. Recombinant Proteins / administration & dosage. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489990.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down


46. Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, Walia T, Naseer N, Baskind P, Ahmed T: Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma; 2006 Mar;47(3):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
  • This report provides long-term results of the treatment of patients with newly-diagnosed AML with a single high dose of mitoxantrone combined with once daily cytarabine.
  • The overall complete remission rate was 64%, with responses in 78% of patients less than 60 years of age and 51% of patients 60 years of age or older.
  • For a sub-set of patients who would be eligible for most US trials, the complete remission rate was 84% in younger patients and 60% in older patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396765.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


47. Ruiz-Argüelles GJ, Morales-Toquero A, Manzano C, Ruiz-Delgado GJ, Jaramillo P, Gonzalez-Carrillo ML, Reyes-Núñez V: t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience. Hematology; 2006 Aug;11(4):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience.
  • We analyze the prevalence and clinical features of a group of patients with t(8;21) (q22;q22) acute myeloblastic leukemia, identified in a single institution in México over a 10-year period.
  • According to the French-American-British (FAB) morphological classification of leukemia, the morphology was M2 in four cases, M4 in three cases, M3 in one case and M0 in one.
  • In addition to the myeloid markers, lymphoid markers were identified in 6 patients.
  • Patients were induced to remission with combined chemotherapy and three subsequently underwent bone marrow transplantation (BMT).
  • In this single-center experience in México, we found that the t(8;21) (q22;q22) variant of leukemia was more frequent than in Caucasian populations, that the co-expression of lymphoid markers in the blast cells is very frequent and that this malignancy is associated with a relatively good prognosis.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid / genetics. Oncogene Proteins, Fusion / genetics. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Prevalence. Prospective Studies. Remission Induction. Salvage Therapy. Transplantation, Autologous / statistics & numerical data. Transplantation, Homologous / statistics & numerical data. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178661.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 80168379AG / Doxorubicin
  •  go-up   go-down


48. Basak G, Torosian T, Snarski E, Niesiobedzka J, Majewski M, Gronkowska A, Urbanowska E, Jedrzejczak W: Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia. Ann Transplant; 2010 Apr-Jun;15(2):68-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
  • BACKGROUND: The T315I mutation of BCR/ABL gene is known to produce complete resistance of chronic myelogenous leukemia (CML) to all currently available BCR/ABL inhibitors.
  • Despite satisfactory hematological remission, he failed to achieve complete cytogenetic remission within the first year of treatment.
  • The course of transplantation was complicated by staphylococcal sepsis, grade I skin acute GvHD and limited chronic skin GVHD.
  • However, the goal of alloSCT was achieved and the patient remains in complete molecular remission at week +68 post-transplantation.
  • [MeSH-major] Genes, abl. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Mutation, Missense
  • [MeSH-minor] Adult. Amino Acid Substitution. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Humans. Leukemia, Myeloid, Accelerated Phase / drug therapy. Leukemia, Myeloid, Accelerated Phase / genetics. Leukemia, Myeloid, Accelerated Phase / therapy. Male. Protein Kinase Inhibitors / pharmacology. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657522.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


49. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


50. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE: Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant; 2008 Jun;14(6):672-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
  • To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect.
  • Patients transplanted with Bu-Flu in the first complete remission (CR1) had a 3-year overall survival and event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-year EFS of 83%.
  • These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489993.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 2P01 CA55164; United States / NCI NIH HHS / CA / P01 CA055164-160020; United States / NCI NIH HHS / CA / 2P30CA16672-26; United States / NCI NIH HHS / CA / P01 CA055164
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS52878; NLM/ PMC4230823
  •  go-up   go-down


51. Khalil F, Cualing H, Cogburn J, Miles L: The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study. Arch Pathol Lab Med; 2007 Aug;131(8):1281-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
  • OBJECTIVE: To study the rate of recovery of bone marrow in patients given myelosuppressive therapy for acute myelogenous leukemia, establish the histologic criteria of recovered marrow, and correlate the recovery pattern with those patients who received a bone marrow transplant by using histology, peripheral blood, immunophenotyping, and computerized morphometry and mathematical slope equation.
  • These patients were divided into 2 groups: 1 group of 28 cases diagnosed with acute myeloid leukemia, the majority treated with cytarabine (Ara-C) infusion for 7 days and daunorubicin intravenously daily for 3 days (7+3 regimen), and the other control group of 23 cases treated with chemotherapy or allogeneic bone marrow transplantation for a variety of hematologic malignancies.
  • We used morphometry to calculate the cellularity and myeloid to erythroid ratio and quantified megakaryocytes CD10 versus time from day 14 onward.
  • After regenerative hyperplasia, the cellularity plateaus, the myeloid to erythroid ratio, and the megakaryocytes even out with platelet normalization, and the early CD10+ B cells rise from day 40 onward, P = .01.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / physiology. Bone Marrow Transplantation. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / physiopathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Biopsy. Blood Cell Count. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Image Processing, Computer-Assisted. Immunophenotyping. Male. Middle Aged. Recovery of Function. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683190.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


52. Fujita A, Fujisawa S, Hyo R, Kuwabara H, Yamazaki E, Tomita N, Ishigatsubo Y: [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia]. Rinsho Ketsueki; 2008 Jan;49(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
  • A 42-year-old woman was admitted to our hospital with acute myelogenous leukemia.
  • After receiving one cycle of induction therapy, she achieved complete remission and blood group A antigen was proven on her red blood cells.
  • [MeSH-major] ABO Blood-Group System / immunology. Blood Grouping and Crossmatching. Leukemia, Myeloid, Acute / blood
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Remission Induction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277597.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


53. Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K: Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant; 2005 Feb;11(2):122-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
  • Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML).
  • To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory.
  • We evaluated the effect of CD34(+) cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1).
  • The high CD34(+) cell dose patients had better overall survival (5-year overall survival rate, 75% +/- 6% vs 52% +/- 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% +/- 6% vs 44% +/- 9%; P = .04).
  • CD34(+) cell dose was the only independent prognostic factor in overall survival and leukemia-free survival.
  • There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34(+) cell dose groups.
  • We confirmed that high CD34(+) cell dose favorably affects the outcomes in allogeneic BMT for AML.
  • The effort to attain a high CD34(+) cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1.
  • [MeSH-major] Antigens, CD34 / analysis. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Leukemia, Myeloid, Acute. Tissue Donors
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Leukocyte Count. Male. Middle Aged. Recurrence. Siblings. Transplantation, Homologous. Treatment Outcome


54. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM: Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia; 2005 Jun;19(6):990-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 24 patients (median age 58; range, 27-71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were not candidates for conventional hematopoietic cell transplantation (HCT), received nonmyeloablative HCT from HLA-matched siblings a median of 28.5 (range, 11-271) months after diagnosis.
  • With a median follow-up of 36 (range, 4-49) months, 13 of 24 patients (54%) were alive and in complete remission.
  • The proportions of grade II, III, and IV acute GVHD were 38, 4, and 8%, respectively.
  • This study shows encouraging remission rates for patients with CML not eligible for conventional allografting.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800667.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA49605; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


55. Konuma T, Tomonari A, Takahashi S, Ooi J, Tsukada N, Yamada T, Sato H, Nagayama H, Iseki T, Tojo A, Asano S: Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia. Int J Hematol; 2006 May;83(4):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia.
  • Patient 1 is a 32-year-old woman with acute myelogenous leukemia (AML)-M5a who underwent CBT.
  • Patient 2 is a 42-year-old man with AML-M4 who underwent CBT.
  • [MeSH-major] Autoimmune Diseases / blood. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute. Thyrotoxicosis / blood
  • [MeSH-minor] Adult. Autoantibodies / blood. Autoantibodies / immunology. Female. Humans. Iodide Peroxidase / immunology. Male. Remission, Spontaneous. Thyroxine / blood. Thyroxine / immunology. Transplantation, Homologous. Triiodothyronine / blood. Triiodothyronine / immunology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Aug;98(2):453-7 [9266950.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):3-5 [1727826.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):406-11 [11233902.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5810-4 [15531546.001]
  • [Cites] Br J Haematol. 1993 Dec;85(4):778-82 [7918043.001]
  • [Cites] Transplantation. 1987 Sep;44(3):463-4 [3307069.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1347-9 [11223977.001]
  • [Cites] Bone Marrow Transplant. 1990 Jul;6(1):49-51 [2390632.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):660-3 [11736951.001]
  • [Cites] Bone Marrow Transplant. 1995 Jan;15(1):71-6 [7742758.001]
  • [Cites] Br J Haematol. 1990 Jan;74(1):118-9 [2310693.001]
  • [Cites] N Engl J Med. 1985 Feb 28;312(9):546-52 [3881675.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2965-71 [12843128.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Blood. 2004 Jan 15;103(2):489-91 [12933570.001]
  • [Cites] Bone Marrow Transplant. 1992 Oct;10(4):397-8 [1422500.001]
  • (PMID = 16757437.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


56. Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ: Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol; 2005 Jul;130(2):233-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
  • Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) was used to determine gene signatures.
  • The expression profile of the 17 top-ranked genes distinguishing AML and ALL were measured by RT-PCR in five ALL, 26 AML, 12 AML remission, four chronic myeloid leukaemia (CML) and nine morphologically normal BM samples.
  • All but two of the genes measured showed similar expression in AML and ALL to that reported previously.
  • Specifically, c-MYB (P </= 0.04) was significantly increased in ALL in the total fraction, whilst HOXA9 (P </= 0.19) and cystatin c (P </= 0.01) were increased in AML in the CD34(+) and CD34(-) fractions, respectively. c-MYB, hSNF2, RBAP48, HKRT-1, LYN, CD33, Adipsin and HOXA9 were increased in AML compared with remission AML, indicating an ability to determine disease activity.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029452.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA, Neoplasm
  •  go-up   go-down


57. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Muccioli G, Viola A, Pane F, Palmieri S: Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. Biol Blood Marrow Transplant; 2010 Jul;16(7):1018-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
  • Mutations of the nucleophosmin gene (NPM1), in the absence of concurrent FLT3-internal tandem duplication (FLT3-ITD) have impressive prognostic value in patients with acute myelogenous leukemia (AML), carrying normal karyotype (NK).
  • In this study we describe treatment results from a series of 19 patients with NPM+/FLT3- autografted in first complete remission (CR) after conditioning with a regimen, named BuI, based on high-dose continuous infusion of idarubicin and Busulfan.
  • Ninety-nine consecutive patients (median age of 54 years) with NK AML autografted in first CR were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Mutation. Nuclear Proteins / genetics. Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prognosis. Treatment Outcome. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BUSULFAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20172040.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
  •  go-up   go-down


58. Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V, Martinelli G, Rosti G, Foà R, Baccarani M, Alimena G: Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res; 2010 Feb;34(2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
  • Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs).
  • Three patients experienced acute and chronic graft-versus-host disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / administration & dosage. Thiazoles / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Dasatinib. Drug Resistance, Neoplasm. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines. Remission Induction / methods. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [CommentIn] Leuk Res. 2010 Feb;34(2):137-8 [19651441.001]
  • (PMID = 19481800.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


59. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR: Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood; 2010 Nov 18;116(20):4251-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.
  • We hypothesized that comprehensive profiling of C&Ckine expression in leukemia would provide greater insight compared with individual analyses.
  • We used multiplex array technology to simultaneously measure the level of 27 C&Ckines in serum from 176 acute myelogenous leukemia (AML) and 114 myelodysplastic syndrome (MDS) patients and 19 normal controls.
  • C&Ckine levels in AML and MDS differed significantly from normal controls (5 higher, 13 lower) but were similar to each other for 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in AML and vascular endothelial growth factor A higher in MDS.
  • Levels did not correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytognetic abnormalities in AML.
  • In newly diagnosed AML, 8 C&Ckine signatures, distinct from the normal control signature, were observed.
  • These signatures had prognostic impact, affecting remission, primary resistance, relapse rates, and overall survival, individually (P = .003) and in multivariable analysis (P = .004).
  • These patterns suggest specific therapeutic interventions to investigate in subsets of AML patients.
  • In conclusion, C&Ckine expression in AML and MDS differs from normal, is similar with one another, and forms recurrent patterns of expression with prognostic relevance.
  • [MeSH-major] Chemokines / blood. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Multivariate Analysis. Principal Component Analysis. Prognosis. Survival Analysis. Treatment Outcome. Young Adult


60. Thomas X, Elhamri M, Chelghoum Y, Reman O, Arnaud P, Raffoux E, Le QH, Tavernier E, Dombret H, Michallet M: Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. Ann Hematol; 2005 Jun;84(6):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
  • Following a dose-escalation study performed to assess the maximally tolerated dose of high-dose mitoxantrone in a single injection combined with chemotherapy, a phase II trial (EMA 2000 regimen) was performed in patients with refractory or relapsed acute myelogenous leukemia (AML) between October 2000 and December 2003.
  • Overall, 39 patients (63%) achieved complete remission (CR).
  • Four patients died during remission induction, and 19 patients had resistant disease.
  • The predominant non-hematologic toxicity was infection, with 53% severe infections.
  • EMA chemotherapy using a single injection of mitoxantrone is effective in the treatment of high-risk AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Bone Marrow Transplantation. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Infection / etiology. Infusions, Intravenous. Life Tables. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Risk. Stomatitis / chemically induced. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782343.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


61. Walther JU, Pohl I, Rausch A, Fuehrer M: Proliferation studies on chromosome preparations of bone marrow in hematological disease. Oncol Rep; 2006 Oct;16(4):893-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The disorders studied were: Acute lymphoblastic leukemia (ALL) (N=107), chronic myeloid leukemia (CML) (N=166) and aplastic anemia in childhood (AA) (N=39).
  • The most important findings include: i) ALL: Immunological subtypes can be differentiated according to their proliferation profile; there is a striking difference between childhood and adult ALL in proliferation activity; most importantly initial proliferation is much higher in patients who will relapse than in those with stable remission.
  • [MeSH-major] Bone Marrow Cells / cytology. Chromosomes / ultrastructure. Hematologic Neoplasms / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic. Bone Marrow / metabolism. Cell Line, Tumor. Cell Proliferation. Child. History, Ancient. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969511.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


62. Usuki K, Urabe A, Ikeda Y, Ohashi Y, Mizoguchi H, Takaku F, Japan IL-11 Study Group: A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol; 2007 Jan;85(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.
  • To investigate the efficacy of using recombinant human interleukin 11 (rhIL-11) to reduce the need for platelet transfusions, we performed a randomized, double-blind phase II/III study with 110 acute myelogenous leukemia (AML) patients in the first complete remission.
  • These results show that rhIL-11 does not reduce the platelet transfusion requirement in AML patients, but the retrospective analysis confirms the previous finding that rhIL-11 reduces infection in patients undergoing chemotherapy.
  • [MeSH-major] Interleukin-11 / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Double-Blind Method. Female. Humans. Infection / drug therapy. Infection / etiology. Male. Middle Aged. Placebos. Platelet Transfusion. Recombinant Proteins / therapeutic use. Retrospective Studies. Stomatitis / drug therapy. Stomatitis / etiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 May 15;93(10):3467-72 [10233899.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1223-6 [1682642.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):319-26 [8547068.001]
  • [Cites] Transfusion. 1998 Jul;38(7):625-36 [9683100.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):49-58 [15606549.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4165-72 [11689585.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Blood. 1988 Sep;72(3):970-7 [3416080.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1018-27 [10400417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):765-9 [1825140.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):677-83 [14530872.001]
  • [Cites] N Engl J Med. 1997 Dec 25;337(26):1870-5 [9407153.001]
  • [Cites] Blood. 1996 May 1;87(9):3607-14 [8611684.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):103-12 [11841402.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3368-77 [9363868.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1499-506 [8123841.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4710-8 [9389686.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1519-38 [11230498.001]
  • [Cites] N Engl J Med. 1997 Feb 6;336(6):404-9 [9010146.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):265-9 [3567081.001]
  • [Cites] Blood. 1993 Jan 1;81(1):27-34 [8417798.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3694-701 [10572081.001]
  • [Cites] Eur J Haematol. 1993 Mar;50(3):160-7 [8472811.001]
  • [Cites] Blood. 1992 Jan 15;79(2):327-31 [1370382.001]
  • [Cites] Blood. 1993 Feb 15;81(4):901-8 [8427998.001]
  • [Cites] Leukemia. 1996 Jun;10(6):964-9 [8667653.001]
  • [Cites] Biol Blood Marrow Transplant. 1998;4(3):134-41 [9923411.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4343-9 [12036860.001]
  • [Cites] Ann Intern Med. 1997 May 1;126(9):673-81 [9139552.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2954-65 [9256140.001]
  • [Cites] Oral Oncol. 2000 Jul;36(4):373-81 [10899677.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2530-5 [10753831.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3897-908 [9166826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7512-6 [2145578.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3):253-60 [9685171.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):275-80 [12559860.001]
  • [Cites] N Engl J Med. 1990 Jun 7;322(23):1646-51 [2342524.001]
  • [Cites] Blood. 1993 Mar 15;81(6):1586-92 [8453105.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S53-5 [15250022.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1448-51 [1832057.001]
  • [Cites] Blood. 1996 May 1;87(9):3615-24 [8611685.001]
  • [Cites] Blood. 1994 Jan 1;83(1):33-7 [8274749.001]
  • (PMID = 17261503.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Placebos; 0 / Recombinant Proteins
  •  go-up   go-down


63. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer; 2005 Apr 15;103(8):1659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML).
  • METHODS: The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
  • RESULTS: In CP, hematologic remission was achieved in 97% and major (MCR) and complete cytogenetic remission (CCR) in 61% and 49% of patients, respectively.
  • In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively.
  • Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Female. Humans. Imatinib Mesylate. Interferon-alpha / adverse effects. Male. Middle Aged. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15747376.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


64. Ataergin S, Arpaci F, Cetin T, Guran S, Yakicier C, Beyzadeoglu M, Ozet A: Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia. Am J Hematol; 2006 May;81(5):370-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia.
  • A 38-year-old female with chronic myeloid leukemia underwent an allogeneic bone marrow transplantation from her full-matched brother.
  • Eleven months later, she readmitted with an acute leukemia that was shown to be of donor origin.
  • The patient never achieved a remission even after chemotherapies with cytarabine and mitoxantrone, donor lymphocyte infusion, and second allogeneic peripheral blood stem cell transplantation.
  • Donor cell leukemia (DCL) is sometimes misdiagnosed as relapse by clinicians and the real incidence may be higher than expected.
  • Cytogenetic and molecular techniques may be helpful to clarify the issue of the leukemia.
  • The current case is another case of DCL reported in the literature after an allogeneic transplant for a kind of leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Transplantation Chimera / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Y. Fatal Outcome. Female. Humans. Male. Philadelphia Chromosome. Tissue Donors. Transplantation, Homologous


65. Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL: Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. Biol Blood Marrow Transplant; 2007 Jun;13(6):724-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
  • The outcome of 55 patients who underwent matched unrelated donor (MUD) transplantation for acute myelogenous leukemia (AML) following a conditioning regimen of cyclophosphamide and total-body irradiation (TBI) with the addition of Alemtuzumab 10 mg/kg/day on days -5 to -1 is described.
  • Forty-one patients were transplanted in complete remission (CR) (20 in CR1, 20 in CR2, and 1 in CR3), and 14 were not in remission at the time of transplantation as they were refractory to chemotherapy either at induction or at relapse.
  • The group consisted of adult patients with a median age of 37 years.
  • Grade II-IV acute GVHD occurred in only 2 patients.
  • The 5-year cumulative survival for the whole group was 38% and was 49% for those in remission at transplantation.
  • Seven of the 12 patients transplanted in CR1 with adverse risk cytogenetics remain alive and in remission, and the predicted 5-year overall survival (OS) for this group is 50%.
  • These results support the use of Alemtuzumab for unrelated donor hematopoietic stem cell transplant (HSCT) for poor risk AML in CR1 and for relapsed AML in CR2.
  • The addition of Alemtuzumab is highly effective in preventing both rejection and severe acute and extensive chronic GVHD without an increased relapse risk.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibodies, Monoclonal, Humanized. Cause of Death. Cyclophosphamide / therapeutic use. Female. Graft Rejection / prevention & control. Graft vs Host Disease / prevention & control. Histocompatibility Testing. Humans. Longitudinal Studies. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Survival Analysis. Tissue Donors. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531783.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Myeloablative Agonists; 3A189DH42V / alemtuzumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


66. Silva PM, Lourenço GJ, Bognone RA, Delamain MT, Pinto-Junior W, Lima CS: Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia. Leuk Res; 2006 Jan;30(1):115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.
  • The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or acute leukaemias is rare.
  • In chronic myeloid leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described associated with the acceleration of disease or onset of blast crisis.
  • We report on a patient with chronic phase of CML and both acquired t(9;22)(q34;q11) and inherited inv(16)(p13q22), who obtained a complete remission of the disease after bone marrow transplant.
  • [MeSH-major] Blast Crisis / pathology. Chromosome Inversion. Chromosomes, Human, Pair 16. Genetic Diseases, Inborn / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Female. Humans. Remission Induction. Translocation, Genetic


67. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S: Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant; 2005 Feb;11(2):108-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
  • Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute myelogenous leukemia or myelodysplastic syndromes.
  • Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first untreated relapse at the time of transplantation.
  • These data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory myeloid leukemias.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous. Treatment Outcome


68. Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Gluck S, Stewart K, Sheridan D, Canadian Leukemia Studies Group: Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. Leuk Lymphoma; 2006 Apr;47(4):697-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
  • PURPOSE: The Canadian Leukemia Studies Group (CLSG) sought to test the safety and efficacy of response-adapted, non-cross resistant chemotherapy in de novo acute myeloid leukemia (AML).
  • As consolidation, patients achieving complete remission (CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE.
  • RESULTS: 76% of all patients achieved remission after IDAC +/- NOVE, 81% in patients aged < or =60 years and 67% in patients aged >60.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Time Factors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690529.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


69. Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA: Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma; 2006 Aug;47(8):1583-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
  • In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.
  • Complete cytogenetic and morphologic remission of AML was evident on follow-up marrow aspirate and biopsy specimens from all patients.
  • In two of the four study patients, the disease remains in complete remission and the patients have an excellent quality of life (Eastern Cooperative Oncology Group performance status 0; no medications) and no organ toxicity more than 2 years and more than 4 years, respectively, after their blood and bone marrow transplantations.
  • Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Bone Marrow / radiation effects. Dose-Response Relationship, Radiation. Humans. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Quality of Life. Remission Induction / methods. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966270.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
  •  go-up   go-down


70. Cohen PR: Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis; 2007;2:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
  • Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.
  • The malignancy-associated Sweet's syndrome (MASS) can occur as a paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is most commonly related to acute myelogenous leukemia.
  • The symptoms and lesions of Sweet's syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence may follow either spontaneous remission or therapy-induced clinical resolution.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Neutrophilic dermatosis, acute febrile.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1971 Jan;103(1):81-4 [5539508.001]
  • [Cites] Dermatologica. 1971;143(3):153-9 [5131096.001]
  • [Cites] Australas J Dermatol. 1971 Dec;12(3):172-7 [5146931.001]
  • [Cites] Arch Dermatol. 1975 Nov;111(11):1461-3 [1239237.001]
  • [Cites] Am J Med. 1976 Sep;61(3):424-32 [961707.001]
  • [Cites] J Rheumatol. 1977 Summer;4(2):201-6 [881698.001]
  • [Cites] S Afr Med J. 1978 Feb 18;53(7):253-6 [653521.001]
  • [Cites] South Med J. 1978 Nov;71(11):1350-2 [280960.001]
  • [Cites] Rev Prat. 1999 Feb 15;49(4):356-8 [10319682.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):838-41 [10321630.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1174-5 [10354095.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):126-9 [10367792.001]
  • [Cites] Pediatr Cardiol. 1999 Jul-Aug;20(4):295-7 [10368458.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):247-52 [10380046.001]
  • [Cites] Pediatr Infect Dis J. 1999 Jun;18(6):568-70 [10391198.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):169-70 [10417544.001]
  • [Cites] Arch Neurol. 1999 Aug;56(8):1010-3 [10448808.001]
  • [Cites] Br J Dermatol. 1964 Aug-Sep;76:349-56 [14201182.001]
  • [Cites] Br J Dermatol. 2004 Nov;151(5):1096-100 [15541094.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):938-41 [15569025.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):168-9 [15608327.001]
  • [Cites] J Am Acad Dermatol. 2005 Feb;52(2):367-9 [15692491.001]
  • [Cites] Orbit. 2005 Mar;24(1):55-7 [15764119.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):368-70 [15781678.001]
  • [Cites] Can J Ophthalmol. 2005 Feb;40(1):90-2 [15825540.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):901-5 [15858487.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):927-8 [15858502.001]
  • [Cites] Neurology. 2005 May 24;64(10):1756-61 [15911805.001]
  • [Cites] Hautarzt. 1988 Oct;39(10):658-61 [3069805.001]
  • [Cites] Am J Dermatopathol. 1989 Apr;11(2):99-111 [2653084.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):677-80 [2715414.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):339-43 [2526826.001]
  • [Cites] Am J Hematol. 1989 Oct;32(2):134-7 [2667344.001]
  • [Cites] Cutis. 1989 Aug;44(2):125-9 [2758862.001]
  • [Cites] Cutis. 1989 Aug;44(2):157-9 [2758865.001]
  • [Cites] Clin Exp Dermatol. 1988 Sep;13(5):344-6 [3256451.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1103-4 [17034566.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1254-5 [17040460.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1365-8 [17076728.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):1066-71 [17097401.001]
  • [Cites] Int J Dermatol. 2007 Jan;46(1):106-11 [17214733.001]
  • [Cites] Australas J Dermatol. 2007 Feb;48(1):50-3 [17222305.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S61-2 [17224394.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):480-5 [17300237.001]
  • [Cites] Intern Med. 2007;46(4):153-4 [17301507.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):275-6 [17310019.001]
  • [Cites] Rev Med Liege. 2006 Dec;61(12):834-6 [17313120.001]
  • [Cites] Presse Med. 2007 Mar;36(3 Pt 1):419-24 [17321363.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):243-7 [17352721.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):258-61 [17352724.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):690-3 [17367621.001]
  • [Cites] Ann Dermatol Venereol. 2007 Feb;134(2):151-4 [17375012.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Actas Dermosifiliogr. 2007 Mar;98(2):102-4 [17397596.001]
  • [Cites] Am J Dermatopathol. 2007 Apr;29(2):125-33 [17414432.001]
  • [Cites] J Neurol. 2003 Jun;250(6):770-1 [12862039.001]
  • [Cites] Actas Dermosifiliogr. 2005 Jun;96(5):315-6 [16476395.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):206-7 [16487091.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S122-6 [16488324.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):235-40 [16490855.001]
  • [Cites] Korean J Intern Med. 2005 Dec;20(4):346-8 [16491836.001]
  • [Cites] Clin Rheumatol. 2006 Mar;25(2):268-72 [15902518.001]
  • [Cites] J Otolaryngol. 2006 Apr;35(2):144-7 [16527036.001]
  • [Cites] J Infect. 2006 May;52(5):e155-7 [16213026.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Apr;20(4):401-5 [16643136.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):677-80 [16796626.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):702-8 [16796632.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1070-1 [16924066.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1170-6 [16983004.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):148 [16856884.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1089-90 [17034556.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1099-101 [17034564.001]
  • [Cites] J Am Acad Dermatol. 1998 Dec;39(6):940-3 [9843005.001]
  • [Cites] Br J Dermatol. 1998 Sep;139(3):555-6 [9767320.001]
  • [Cites] Eur J Dermatol. 1998 Oct-Nov;8(7):503-5 [9854164.001]
  • [Cites] Br J Dermatol. 1998 Oct;139(4):744-5 [9892926.001]
  • [Cites] Br J Dermatol. 1998 Nov;139(5):930-1 [9892977.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):709-10 [9852556.001]
  • [Cites] Arch Dermatol. 1999 Jan;135(1):62-6 [9923783.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):440-2 [9972982.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):275-9 [10025763.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 2):331-4 [10025862.001]
  • [Cites] Cutis. 1999 Mar;63(3):177-9 [10190073.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):565-6 [10233302.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):341-3 [15223465.001]
  • [Cites] Ann Dermatol Venereol. 2004 Apr;131(4):369-72 [15258512.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):474-5 [15337997.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):716-7 [15482306.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):745-6 [15482319.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):720-2 [15485526.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):772-7 [15485540.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):396-9 [15491764.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):639-42 [8157792.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):415-7 [7515269.001]
  • [Cites] Clin Exp Dermatol. 1994 May;19(3):274-7 [8033398.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):645-8 [7519039.001]
  • [Cites] J Dermatol. 1994 May;21(5):341-6 [8051321.001]
  • [Cites] Int J Dermatol. 1994 Jun;33(6):425-32 [8056477.001]
  • [Cites] Acta Derm Venereol. 1994 May;74(3):229-30 [7915473.001]
  • [Cites] J Am Acad Dermatol. 1994 Oct;31(4):535-56; quiz 557-60 [8089280.001]
  • [Cites] Br J Dermatol. 1979 Jan;100(1):93-9 [427014.001]
  • [Cites] Dermatologica. 1980;160(5):341-7 [7364144.001]
  • [Cites] Br J Dermatol. 1981 Oct;105(4):483 [7295564.001]
  • [Cites] Postgrad Med. 1982 Jan;71(1):55-60 [7054779.001]
  • [Cites] S Afr Med J. 1982 Sep 4;62(11):375-8 [7112306.001]
  • [Cites] Clin Rheum Dis. 1982 Aug;8(2):427-41 [6754235.001]
  • [Cites] Br J Dermatol. 1983 Jan;108(1):99-101 [6821647.001]
  • [Cites] J Pediatr. 1983 Feb;102(2):243-8 [6822929.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1518-26 [6572088.001]
  • [Cites] Arch Dermatol. 1983 Jul;119(7):610-1 [6574727.001]
  • [Cites] J Am Acad Dermatol. 1983 Jul;9(1):77-81 [6886108.001]
  • [Cites] Cutis. 1983 Aug;32(2):152-4 [6617253.001]
  • [Cites] Arch Intern Med. 1983 Oct;143(10):1993-5 [6625786.001]
  • [Cites] Arch Neurol. 1983 Dec;40(13):829 [6639416.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):751-8 [6358279.001]
  • [Cites] Arch Dermatol. 1984 Feb;120(2):245-7 [6696481.001]
  • [Cites] Blut. 1984 May;48(5):297-305 [6722359.001]
  • [Cites] Arch Dermatol. 1985 Jun;121(6):789-91 [4004304.001]
  • [Cites] Dermatologica. 1985;171(2):102-5 [4043468.001]
  • [Cites] Presse Med. 1985 Sep 14;14(30):1599-601 [2995962.001]
  • [Cites] Lupus. 2005;14(5):399-402 [15934441.001]
  • [Cites] South Med J. 2005 May;98(5):570-2 [15954518.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S135-8 [16021163.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):834-42 [16027297.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):881-4 [16027305.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):887-9 [16027306.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):893-5 [16027307.001]
  • [Cites] Clin Dev Immunol. 2005 Jun;12(2):145-9 [16050146.001]
  • [Cites] Int J Dermatol. 2005 Aug;44(8):677-80 [16101872.001]
  • [Cites] Retina. 2005 Sep;25(6):800-2 [16141877.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):597-9 [16164716.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):634-7 [16164726.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):142 [16197442.001]
  • [Cites] Digestion. 2005;72(2-3):195-200 [16179788.001]
  • [Cites] Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):376-9 [16268426.001]
  • [Cites] Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):883-5 [16327718.001]
  • [Cites] Int J Dermatol. 2005 Nov;44(11):946-7 [16336530.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):525-9 [16354254.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):530-5 [16354255.001]
  • [Cites] J Indian Med Assoc. 2005 Aug;103(8):433-5 [16363199.001]
  • [Cites] J Assoc Physicians India. 2005 Aug;53:728-30 [16398086.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):364 [16157374.001]
  • [Cites] Int J Dermatol. 2005 Dec;44(12):1051-3 [16409276.001]
  • [Cites] Arch Dermatol. 2006 Jan;142(1):57-63 [16415387.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):51-2 [16426377.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):70-80 [16426383.001]
  • [Cites] Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):1003-6 [16446647.001]
  • [Cites] Haematologica. 2005 Dec;90(12 Suppl):ECR43 [16464758.001]
  • [Cites] South Med J. 2007 Oct;100(10):1057-8 [17943059.001]
  • [Cites] Pediatrics. 1999 Nov;104(5 Pt 1):1142-4 [10545563.001]
  • [Cites] Clin Exp Dermatol. 1999 Sep;24(5):368-71 [10564323.001]
  • [Cites] Australas J Dermatol. 1999 Nov;40(4):204-7 [10570557.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1887-97 [3058878.001]
  • [Cites] J Am Acad Dermatol. 1988 Dec;19(6):983-1005 [3060489.001]
  • [Cites] Am Fam Physician. 1989 Mar;39(3):199-204 [2646883.001]
  • [Cites] Ann Intern Med. 1989 Apr 1;110(7):573-4 [2923392.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):334-59 [9208889.001]
  • [Cites] J Am Acad Dermatol. 1997 Jul;37(1):123-4 [9216537.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):54-6 [9330058.001]
  • [Cites] Int J Dermatol. 1997 Sep;36(9):717-8 [9352420.001]
  • [Cites] Br J Dermatol. 1997 Oct;137(4):609-13 [9390341.001]
  • [Cites] Thorac Cardiovasc Surg. 1997 Oct;45(5):247-8 [9402666.001]
  • [Cites] Med Clin (Barc). 1997 Nov 1;109(15):588-91 [9441195.001]
  • [Cites] Int J Dermatol. 1997 Nov;36(11):837-44 [9427076.001]
  • [Cites] Br J Dermatol. 1989 Sep;121(3):413-5 [2803964.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):726-9 [2809903.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):730-4 [2809904.001]
  • [Cites] Vestn Dermatol Venerol. 1989;(11):67-9 [2618175.001]
  • [Cites] Neth J Med. 1990 Feb;36(1-2):62-8 [2278538.001]
  • [Cites] J Rheumatol. 1990 May;17(5):682-4 [2193156.001]
  • [Cites] Rev Clin Esp. 1990 Apr;186(6):264-9 [2203115.001]
  • [Cites] Am J Med. 1990 Sep;89(3):396 [2203266.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):247-9 [2212120.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):503-7 [2212153.001]
  • [Cites] Int J Dermatol. 1990 Dec;29(10):737 [2269574.001]
  • [Cites] Acta Haematol. 1990;84(4):207-8 [2125789.001]
  • [Cites] Dermatologica. 1991;182(1):43-6 [1826487.001]
  • [Cites] Br J Dermatol. 1991 Apr;124(4):348-53 [2025555.001]
  • [Cites] J R Soc Med. 1991 May;84(5):307-8 [2041012.001]
  • [Cites] Acta Derm Venereol. 1991;71(1):77-9 [1676226.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):858-60 [2099706.001]
  • [Cites] Australas J Dermatol. 1991;32(1):55-9 [1834046.001]
  • [Cites] Am J Med. 1991 Nov;91(5):553-4 [1951419.001]
  • [Cites] Dermatologica. 1991;183(3):230-3 [1743390.001]
  • [Cites] Acta Derm Venereol. 2003;83(4):290-1 [12926802.001]
  • [Cites] Br J Dermatol. 2003 Sep;149(3):675-7 [14511020.001]
  • [Cites] Int J Dermatol. 2003 Oct;42(10):761-78 [14521689.001]
  • [Cites] Med Clin (Barc). 2003 Oct 4;121(11):437 [14563281.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):907-9 [14576675.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1374 [14585639.001]
  • [Cites] Korean J Intern Med. 2003 Sep;18(3):187-90 [14619389.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):884 [14616386.001]
  • [Cites] Contact Dermatitis. 2003 Jul;49(1):42 [14641120.001]
  • [Cites] J Cutan Pathol. 2004 Jan;31(1):72-6 [14675289.001]
  • [Cites] J Cutan Pathol. 2004 Feb;31(2):189-94 [14690466.001]
  • [Cites] Int J Dermatol. 2004 Jan;43(1):57-9 [14693024.001]
  • [Cites] QJM. 2004 Jan;97(1):55-6 [14702513.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2):280-5 [14726888.001]
  • [Cites] Clin Nucl Med. 2004 Feb;29(2):91-2 [14734904.001]
  • [Cites] Eye (Lond). 2004 Feb;18(2):214; discussion 214-6 [14762428.001]
  • [Cites] J Laryngol Otol. 2004 Jan;118(1):48-9 [14979973.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Mar;18(2):233 [15009320.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S61-3 [15036943.001]
  • [Cites] Dermatology. 2004;208(2):175 [15057014.001]
  • [Cites] J Fam Plann Reprod Health Care. 2004 Apr;30(2):115-6 [15086998.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5 Suppl):S90-2 [15097938.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):798-9 [15097971.001]
  • [Cites] Int J Dermatol. 2004 Feb;43(2):95-102 [15125498.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):197-9 [15125614.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):570-4 [15148101.001]
  • [Cites] J Med Assoc Thai. 2004 May;87(5):567-72 [15222531.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):283-5 [15224368.001]
  • [Cites] Br J Haematol. 1993 Sep;85(1):191-2 [7504506.001]
  • [Cites] Dermatology. 1993;187(4):303-5 [8274797.001]
  • [Cites] Acta Derm Venereol. 1993 Oct;73(5):380-1 [7904408.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):293-7 [8294584.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):297-300 [8294585.001]
  • [Cites] J Cutan Pathol. 1993 Oct;20(5):465-78 [7507948.001]
  • [Cites] Clin Exp Dermatol. 1994 Jan;19(1):51-2 [8313637.001]
  • [Cites] South Med J. 1994 Feb;87(2):193-6 [8115882.001]
  • [Cites] Int J Dermatol. 2001 Dec;40(12):791-3 [11903682.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):111-4 [11907794.001]
  • [Cites] Acta Orthop Belg. 2002 Feb;68(1):68-71 [11915462.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):295-7 [11981477.001]
  • [Cites] Int J Dermatol. 2002 Feb;41(2):107-9 [11982648.001]
  • [Cites] Clin Pediatr (Phila). 2002 Apr;41(3):175-7 [11999681.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1087-90 [12072085.001]
  • [Cites] J Occup Environ Med. 2002 Jun;44(6):491-2 [12085472.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1596 [8090038.001]
  • [Cites] Am Fam Physician. 1994 Nov 1;50(6):1273-82 [7942426.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):1045-7 [7962753.001]
  • [Cites] Pediatr Dermatol. 1994 Sep;11(3):237-40 [7971558.001]
  • [Cites] J Rheumatol. 1994 Sep;21(9):1766-8 [7799365.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):192-8 [7829702.001]
  • [Cites] Mayo Clin Proc. 1995 Mar;70(3):234-40 [7861810.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):261-4 [7532508.001]
  • [Cites] J Am Acad Dermatol. 1995 Mar;32(3):533-5 [7868739.001]
  • [Cites] Int J Dermatol. 1995 Jan;34(1):73-4 [7896497.001]
  • [Cites] Australas J Dermatol. 1994;35(2):91-2 [7702496.001]
  • [Cites] Dermatology. 1995;190(2):160-3 [7727840.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):687-90 [7774902.001]
  • [Cites] Mayo Clin Proc. 1995 Jun;70(6):605-6 [7632268.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):144-5 [7601939.001]
  • [Cites] Int J Dermatol. 1995 May;34(5):323-9 [7607792.001]
  • [Cites] Am J Med. 1995 Aug;99(2):207-16 [7625426.001]
  • [Cites] Semin Dermatol. 1995 Jun;14(2):173-8 [7640199.001]
  • [Cites] Postgrad Med J. 1995 Jun;71(836):383 [7644412.001]
  • [Cites] Acta Derm Venereol. 1995 May;75(3):237-9 [7653187.001]
  • [Cites] Pediatr Dermatol. 1985 Nov;3(1):40-4 [3906610.001]
  • [Cites] Dermatol Clin. 1985 Jan;3(1):153-63 [3912087.001]
  • [Cites] Cutis. 1986 Mar;37(3):167-74 [3514153.001]
  • [Cites] Am J Med. 1986 Sep;81(3):558-60 [2944382.001]
  • [Cites] Dermatologica. 1986;173(2):85-9 [3792603.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):251, 254 [2434033.001]
  • [Cites] J Clin Pathol. 1987 Feb;40(2):175-9 [3546396.001]
  • [Cites] Am J Med. 1987 Jun;82(6):1220-6 [3300306.001]
  • [Cites] Cutis. 1987 Aug;40(2):139-42 [3621997.001]
  • [Cites] J Assoc Physicians India. 2002 Oct;50:1322-3 [12568224.001]
  • [Cites] Dermatology. 2003;206(2):81-4 [12592072.001]
  • [Cites] J Cutan Pathol. 2003 Apr;30(4):261-4 [12680958.001]
  • [Cites] Int J Dermatol. 2003 Jun;42(6):438-43 [12786869.001]
  • [Cites] Clin Exp Dermatol. 2003 Jul;28(4):377-9 [12823297.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):132-8 [12833027.001]
  • [Cites] Ann Acad Med Singapore. 2003 May;32(3):411-4 [12854387.001]
  • [Cites] Clin Exp Dermatol. 1987 Sep;12(5):345-9 [3446421.001]
  • [Cites] Tunis Med. 2007 Jan;85(1):49-53 [17424710.001]
  • [Cites] South Med J. 2007 Apr;100(4):414-5 [17458409.001]
  • [Cites] Ann Pharmacother. 2007 May;41(5):802-11 [17426076.001]
  • [Cites] Int J Dermatol. 2007 May;46(5):496-9 [17472681.001]
  • [Cites] Clin Rheumatol. 2007 Jul;26(7):1215-6 [17294051.001]
  • [Cites] Australas J Dermatol. 2007 May;48(2):105-9 [17535199.001]
  • [Cites] Int J Dermatol. 2007 Jun;46(6):571-4 [17550553.001]
  • [Cites] Clin Dermatol. 2007 May-Jun;25(3):326-33 [17560310.001]
  • [Cites] J Cutan Pathol. 2007 Jul;34(7):526-34 [17576331.001]
  • [Cites] Ann Hematol. 2007 Aug;86(8):613-4 [17468870.001]
  • [Cites] Med Sci Monit. 2007 Apr;13(4):CS53-5 [17392656.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):989-90 [8959963.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):995-7 [8959967.001]
  • [Cites] Arch Dermatol. 1996 Dec;132(12):1507, 1510 [8961884.001]
  • [Cites] Br J Dermatol. 1997 Jan;136(1):142-4 [9039324.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):296-7 [9068763.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):436-9 [9091476.001]
  • [Cites] Dermatology. 1997;194(2):182-4 [9094473.001]
  • [Cites] Int J Dermatol. 1997 Apr;36(4):292-3 [9169331.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):135-6 [12461805.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):81-2 [12480678.001]
  • [Cites] Int J Dermatol. 2002 Dec;41(12):928-30 [12492993.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):101-2 [12533182.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):102 [12533183.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1033-4 [10570395.001]
  • [Cites] Br J Ophthalmol. 1998 Mar;82(3):328-9 [9602638.001]
  • [Cites] Br J Dermatol. 1998 Feb;138(2):365-6 [9602899.001]
  • [Cites] Clin Exp Dermatol. 1997 Nov;22(6):269-73 [9604452.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):116-8 [9611384.001]
  • [Cites] Dermatology. 1998;196(3):346-7 [9621146.001]
  • [Cites] Eur Respir J. 1998 Apr;11(4):978-80 [9623707.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):337-8 [9692401.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):178-81 [9722904.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):107-10 [9764159.001]
  • [Cites] Ann Hematol. 1998 Sep;77(3):135-8 [9797084.001]
  • [Cites] Dermatology. 1998;197(2):195-6 [9840982.001]
  • [Cites] Intensive Care Med. 1998 Oct;24(10):1106-9 [9840248.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):766-7 [10583147.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):943-4 [10583195.001]
  • [Cites] J Clin Gastroenterol. 1999 Dec;29(4):349-50 [10599643.001]
  • [Cites] Clin Exp Dermatol. 1999 Nov;24(6):443-5 [10606943.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):83-6 [10634651.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):332-4 [10640926.001]
  • [Cites] Am J Med. 2000 Apr 1;108(5):434-5 [10759106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):477-9 [10760730.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 2):932-5 [10767709.001]
  • [Cites] Arch Dermatol. 2000 May;136(5):673-4 [10815868.001]
  • [Cites] Australas J Dermatol. 1991;32(2):61-4 [1781756.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):734 [1724249.001]
  • [Cites] Arthritis Rheum. 1992 Apr;35(4):484-6 [1567500.001]
  • [Cites] Dermatologica. 1991;183(4):255-64 [1809587.001]
  • [Cites] Ann Intern Med. 1992 Jun 15;116(12 Pt 1):996-8 [1375012.001]
  • [Cites] J Rheumatol. 1992 May;19(5):814-20 [1613717.001]
  • [Cites] Am Rev Respir Dis. 1992 Jul;146(1):269 [1626811.001]
  • [Cites] Cutis. 1992 Jun;49(6):448-50 [1628515.001]
  • [Cites] Intern Med. 1992 May;31(5):686-9 [1504437.001]
  • [Cites] Aust N Z J Ophthalmol. 1992 Aug;20(3):263-5 [1449782.001]
  • [Cites] Int J Dermatol. 1992 Sep;31(9):670-1 [1459771.001]
  • [Cites] Acta Haematol. 1992;88(2-3):154-7 [1466198.001]
  • [Cites] Br J Dermatol. 1992 Nov;127(5):538-9 [1467297.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 2):801-4 [1469130.001]
  • [Cites] Pediatr Dermatol. 1992 Sep;9(3):288-92 [1488383.001]
  • [Cites] Clin Exp Dermatol. 1993 Jan;18(1):47-9 [8440052.001]
  • [Cites] Cutis. 1993 Mar;51(3):175-9 [8444048.001]
  • [Cites] Cutis. 1993 Feb;51(2):112-4 [8453891.001]
  • [Cites] Int J Dermatol. 1993 Apr;32(4):261-8 [8486457.001]
  • [Cites] Arch Ophthalmol. 1993 May;111(5):587-8 [8489431.001]
  • [Cites] Mayo Clin Proc. 1993 Jun;68(6):620-1 [8497142.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):584-6 [8504055.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):149-57 [8339190.001]
  • [Cites] Arch Dermatol. 1993 Aug;129(8):1062-4 [8352617.001]
  • [Cites] Obstet Gynecol Surv. 1993 Aug;48(8):584-7 [8371901.001]
  • [Cites] Br J Haematol. 1993 Jun;84(2):356-8 [7691149.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2723-31 [8402496.001]
  • [Cites] Australas J Dermatol. 1993;34(1):31-3 [8240185.001]
  • [Cites] Korean J Intern Med. 2001 Sep;16(3):218-21 [11769583.001]
  • [Cites] Dermatology. 2002;204(1):84 [11834860.001]
  • [Cites] J Dermatol. 2002 Feb;29(2):91-5 [11890302.001]
  • [Cites] Am J Clin Dermatol. 2002;3(2):117-31 [11893223.001]
  • [Cites] Int J Dermatol. 2002 Jan;41(1):28-31 [11895510.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):345-9 [11902985.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):361-5 [11902987.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):400-3 [11902994.001]
  • [Cites] Clin Dermatol. 2000 May-Jun;18(3):265-82 [10856659.001]
  • [Cites] Arch Intern Med. 2000 Jun 26;160(12):1869 [10871983.001]
  • [Cites] Acta Derm Venereol. 2000 Mar-Apr;80(2):145-6 [10877140.001]
  • [Cites] Eur J Haematol. 2000 Jul;65(1):72-3 [10914942.001]
  • [Cites] Br J Dermatol. 2000 Aug;143(2):449-50 [10951165.001]
  • [Cites] J Am Acad Dermatol. 2000 Oct;43(4):691-7 [11004629.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):429-33 [11048979.001]
  • [Cites] Postgrad Med J. 2000 Nov;76(901):713-4 [11060149.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):914-6 [11069494.001]
  • [Cites] Int J Dermatol. 2000 Oct;39(10):795-8 [11095204.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1322-4 [11122045.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):59-62 [11196274.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):870-4 [11050599.001]
  • [Cites] J Cutan Pathol. 2001 Feb;28(2):90-6 [11168757.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):862-4 [11312438.001]
  • [Cites] Medicine (Baltimore). 2001 May;80(3):173-9 [11388093.001]
  • [Cites] Acta Derm Venereol. 2001 Jan-Feb;81(1):73-4 [11411932.001]
  • [Cites] Am J Med. 2001 Jul;111(1):80-1 [11460854.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):300-2 [11464196.001]
  • [Cites] J Neurol Sci. 2001 Jul 15;188(1-2):95-7 [11489291.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1106-8 [11493115.001]
  • [Cites] Yale J Biol Med. 2001 May-Jun;74(3):165-8 [11501712.001]
  • [Cites] J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4 [11511831.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):590-5 [11568752.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1526-9 [11598485.001]
  • [Cites] Clin Exp Dermatol. 2001 Nov;26(8):668-70 [11722452.001]
  • [Cites] Dermatology. 1995;190(4):335-7 [7655121.001]
  • [Cites] J Am Acad Dermatol. 1995 Sep;33(3):393-410; quiz 410-2 [7544812.001]
  • [Cites] Clin Exp Dermatol. 1995 May;20(3):279-80 [7671433.001]
  • [Cites] Arch Dermatol. 1995 Oct;131(10):1175-7 [7574835.001]
  • [Cites] Aust Fam Physician. 1995 Oct;24(10):1867-9 [8546614.001]
  • [Cites] Am J Med. 1995 Dec;99(6):662-71 [7503090.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):483-6 [8547011.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):490-1 [8547013.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):690 [8596402.001]
  • [Cites] J Am Acad Dermatol. 1996 Mar;34(3):539 [8609279.001]
  • [Cites] Pediatrics. 1996 Mar;97(3):401-3 [8604280.001]
  • [Cites] Leukemia. 1996 Apr;10(4):731-4 [8618455.001]
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23 [8621829.001]
  • [Cites] Cutis. 1996 Feb;57(2):107-10 [8646854.001]
  • [Cites] Adv Dermatol. 1996;11:215-52; discussion 253 [8718480.001]
  • [Cites] Australas J Dermatol. 1996 May;37(2):99-101 [8687337.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Mar;32B(2):133-6 [8736177.001]
  • [Cites] Br J Dermatol. 1996 Apr;134(4):705-9 [8733376.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):282-4 [8689342.001]
  • [Cites] Clin Exp Dermatol. 1996 Mar;21(2):175 [8759219.001]
  • [Cites] Am J Med. 1996 Aug;101(2):231-3 [8757366.001]
  • [Cites] Ann Acad Med Singapore. 1996 Mar;25(2):222-7 [8799010.001]
  • [Cites] J Neurol. 1996 Jul;243(7):556-7 [8836949.001]
  • [Cites] Int J Dermatol. 1996 Jan;35(1):9-15 [8838921.001]
  • [Cites] Respir Med. 1996 Jan;90(1):57-9 [8857328.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):629-31 [8859296.001]
  • [Cites] Haematologica. 1996 Jan-Feb;81(1):54-8 [8900854.001]
  • [Cites] J Rheumatol. 1996 Nov;23(11):1995-8 [8923382.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):301-4 [12100632.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):323-4 [12140489.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):397-8 [12185512.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):558-62 [12207601.001]
  • [Cites] Rheumatology (Oxford). 2002 Sep;41(9):1067-9 [12209043.001]
  • [Cites] Acta Derm Venereol. 2002;82(3):221 [12353722.001]
  • [Cites] Am J Psychiatry. 2002 Nov;159(11):1947 [12411238.001]
  • [Cites] Eur J Radiol. 2002 Nov;44(2):139-42 [12413682.001]
  • (PMID = 17655751.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 435
  • [Other-IDs] NLM/ PMC1963326
  •  go-up   go-down


71. Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ, Lu G: del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet; 2009 Jul;192(1):18-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.
  • The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML).
  • Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three.
  • Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q).
  • Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q).
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 15. Clone Cells / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • [MeSH-minor] Adult. Bone Marrow Cells / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosome Aberrations. Female. Follow-Up Studies. Gene Frequency. Humans. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2004 Jan;17(1):96-103 [14657955.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Jan 15;188(2):118-23 [19100517.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):146-51 [15172752.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):836-42 [15198355.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):671-84, x [15271399.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2632-41 [10594858.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):70-3 [10646855.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3343-56 [11071626.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):437-9 [11231500.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1102-10 [11920481.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1266-72 [12481006.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):74-7 [12794759.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 1;144(1):1-5 [12810248.001]
  • [Cites] Scand J Haematol. 1976 Jul;17(1):17-28 [1066809.001]
  • [Cites] Cancer. 1979 Apr;43(4):1350-7 [445335.001]
  • [Cites] Hum Genet. 1981;58(3):285-93 [6948765.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):535-41 [3965107.001]
  • [Cites] Leuk Res. 1991;15(8):683-91 [1654480.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):35-8 [1913605.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 1:11-5 [8251885.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):124-8 [8603337.001]
  • [Cites] Baillieres Clin Haematol. 1997 Jun;10(2):223-31 [9376661.001]
  • [Cites] Leuk Res. 1998 Sep;22(9):845-7 [9716017.001]
  • [Cites] Curr Opin Hematol. 1998 Jul;5(4):302-8 [9747637.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):164-72 [10403855.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):807-14 [16203287.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1730-8 [16532439.001]
  • [Cites] J Cell Biochem. 2007 Apr 15;100(6):1376-86 [17131381.001]
  • [Cites] Cancer. 2008 May 15;112(10):2112-8 [18348294.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1933-52 [18798533.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4010-22 [14982876.001]
  • (PMID = 19480932.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS627187; NLM/ PMC4167428
  •  go-up   go-down


72. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A: Rapamycin for refractory acute graft-versus-host disease. Transplantation; 2009 Nov 15;88(9):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin for refractory acute graft-versus-host disease.
  • Steroid-refractory acute graft-versus-host disease (GVHD) remains a significant cause of mortality after allogeneic stem-cell transplantation and therapeutic options are not codified.
  • METHODS: In this retrospective single-center study, 22 patients were identified, from October 2004 to February 2008, as having received rapamycin for acute GVHD refractory to one or more lines of treatment.
  • RESULTS: Rapamycin resulted in a rapid and sustained complete remission of GVHD in 72% of heavily pretreated patients.
  • CONCLUSION: Despite a small and heterogeneous population of patients, these results are encouraging and provide a rationale for prospective studies that use rapamycin in steroid-refractory acute GVHD as a second- or third-line agent.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / therapeutic use. Leukemia / surgery. Sirolimus / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bacterial Infections / epidemiology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Middle Aged. Retrospective Studies. Survival Rate. Survivors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898203.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


73. Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L, Planelles D, Larrea L, Martín G, Palau J, Jarque I, Martínez J, de la Rubia J, Moscardó F, Romero M, Luna I, Montava A, Cañabate S, Sanz GF: Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant; 2010 Jan;16(1):86-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.
  • We analyzed the outcome and prognostic factors of 49 adults with high-risk acute myelogenous leukemia (AML) receiving single-unit CBT from unrelated donors after myeloablative (MA) conditioning at a single institution.
  • Cumulative incidence of myeloid and platelet engraftment was 96% and 73% at a median time of 20 and 62 days, respectively.
  • Confidence Interval of graft-versus-host disease (GVHD), acute GVHD (aGVHD) grade II-IV, III-IV, and extensive chronic GVHD (cGVHD) were 26%, 15%, and 30%, respectively.
  • Leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse at 2 years were 42%, 39%, and 19%, respectively.
  • Patients transplanted in first complete remission (CR1) receiving TNC above 2 x 10(7)/kg had a 4-year LFS of 75%.
  • These results show that CBT from unrelated donors is a curative treatment for a substantial number of patients with high-risk AML, particularly if transplant is performed with highly cellular units in patients in first CR.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / analysis. Female. Graft vs Host Disease / epidemiology. Histocompatibility Testing. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Risk Factors. Statistics as Topic. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19744570.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


74. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med; 2007 Jan 25;356(4):348-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.
  • Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first.
  • CONCLUSIONS: In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Female. Humans. Kaplan-Meier Estimate. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Male. Middle Aged. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / mortality. Single-Blind Method. Treatment Outcome


75. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M: Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet; 2010 Nov 16;11:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia (AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid leukemia, and 95 healthy controls.
  • Clinical and follow up data were available for 112 MDS patients and 186 AML patients.
  • There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML.
  • In the MDS group, the GG genotype was significantly associated with shorter complete remission duration, as compared with the TT genotype (P = 0.03).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Genotype. Humans. Leukemia, Lymphocytic, Chronic, B-Cell. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Leukemia, Myeloid, Acute. Middle Aged. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Treatment Outcome. Young Adult


76. Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E: Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res; 2008 May 15;14(10):3077-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
  • PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.
  • Such patients might benefit from additional therapy in complete remission (CR).
  • Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.
  • We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.
  • Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics.
  • CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):672-80 [12760285.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3880-9 [12920034.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1387-94 [17082323.001]
  • [Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • (PMID = 18483374.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
  • [Other-IDs] NLM/ NIHMS281726; NLM/ PMC3074480
  •  go-up   go-down


77. Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, Choudhry VP, Saxena R: Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb Hemost; 2007 Jul;13(3):292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
  • Between January 2001 and December 2003, 67 patients with acute leukemia were evaluated prospectively for hemostatic abnormality at presentation, of which 43 (64.2%) had acute lymphoblastic leukemia and 24 (35.8%) had acute myelogenous leukemia.
  • Disseminated intravascular coagulation was more often associated with bleeding manifestations in acute myelogenous leukemia cases than in acute lymphoblastic leukemia cases.
  • It is recommended that all patients with leukemia be investigated for disseminated intravascular coagulation at presentation.
  • [MeSH-major] Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Incidence. Male. Methotrexate / therapeutic use. Middle Aged. Partial Thromboplastin Time. Prednisone / therapeutic use. Prospective Studies. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17636191.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BFM-86 protocol
  •  go-up   go-down


78. Takeuchi K, Hattori T, Masuda S, Usui S, Oka K, Sakaida H, Majima Y: Cochlear implantation in complete remission in a patient with leukemia. Acta Otolaryngol; 2008 Jul;128(7):821-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation in complete remission in a patient with leukemia.
  • Patients with leukemia have an increased risk of developing sensorineural hearing loss.
  • This is a retrospective review of a profoundly deafened patient with acute myelogenous leukemia who underwent cochlear implantation.
  • The 26-year-old patient was successfully implanted with a Nucleus cochlear implant in the complete remission after peripheral blood stem cell transplantation.
  • To our knowledge, this is the first reported case of successful cochlear implantation in a patient deafened by acute myelogenous leukemia.
  • [MeSH-major] Cochlear Implantation / methods. Hearing Loss, Sensorineural / surgery. Leukemia, Myeloid, Acute / complications
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Peripheral Blood Stem Cell Transplantation / methods. Remission Induction / methods. Speech Perception / physiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568527.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


79. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP: Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma; 2010 Jan;51(1):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
  • Cytarabine resistance characterizes relapsed and refractory acute myelogenous leukemia (AML).
  • We conducted an adaptively randomized study of a combination of azacitidine, a hypomethylating agent, and cytarabine in 34 patients with AML.
  • However, in this advanced AML population, it was difficult to deliver more than one cycle of therapy, and minimal anti-leukemia activity was seen in patients with relapsed/refractory disease.
  • Complete remission was achieved in 2 of 6 minimally pre-treated patients.
  • We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7512-23 [14576855.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Biochim Biophys Acta. 1965 Nov 8;108(3):516-8 [5867538.001]
  • [Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]
  • [Cites] Cancer Res. 1974 Oct;34(10):2482-8 [4137739.001]
  • [Cites] Biochemistry. 1975 Jan 28;14(2):316-26 [47243.001]
  • [Cites] Oncology. 1974;30(5):405-22 [4142650.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2853-7 [50882.001]
  • [Cites] Cancer Res. 1976 Mar;36(3):1114-20 [56229.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2458-66 [78761.001]
  • [Cites] Cell. 1980 May;20(1):85-93 [6156004.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4000-6 [6162541.001]
  • [Cites] Science. 1981 Jan 23;211(4480):393-6 [6164095.001]
  • [Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5029-37 [6091869.001]
  • [Cites] Adv Enzyme Regul. 1985;24:335-54 [2424284.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):257-61 [3035720.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(4):203-10 [2473850.001]
  • [Cites] Blood. 1997 Jul 1;90(1):346-53 [9207471.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1096-103 [9886326.001]
  • [Cites] Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78 [15533764.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3895-903 [16921040.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4225-32 [17634552.001]
  • [Cites] Biometrics. 2007 Jun;63(2):429-36 [17688495.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1366-73 [18523155.001]
  • [Cites] Blood. 2009 Jan 15;113(3):659-67 [18931345.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • (PMID = 20017599.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100632-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632-04; United States / NCI NIH HHS / CA / P50 CA100632-079004; United States / NCI NIH HHS / CA / CA100632-07S1; United States / NCI NIH HHS / CA / P50 CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / P50 CA100632-069004; United States / NCI NIH HHS / CA / CA100632-04; United States / NCI NIH HHS / CA / CA100632-070006; United States / NCI NIH HHS / CA / CA100632-070001; United States / NCI NIH HHS / CA / CA100632-03; None / None / / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-03; United States / NCI NIH HHS / CA / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-069004; United States / NCI NIH HHS / CA / P50 CA100632-070001; United States / NCI NIH HHS / CA / CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632-010007; United States / NCI NIH HHS / CA / P50 CA100632-070006; None / None / / P50 CA100632-010007; United States / NCI NIH HHS / CA / CA100632; United States / NCI NIH HHS / CA / CA100632-079004; United States / NCI NIH HHS / CA / P50 CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-07; United States / NCI NIH HHS / CA / P50 CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-05; United States / NCI NIH HHS / CA / CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-010001; United States / NCI NIH HHS / CA / P50 CA100632-07S1; United States / NCI NIH HHS / CA / CA100632-07; United States / NCI NIH HHS / CA / CA100632-010001
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS200831; NLM/ PMC2876330
  •  go-up   go-down


80. Moon HW, Shin S, Kim HY, Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Chun H, Kim HC, Park CJ, Min YH, Lee DS: Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia; 2006 Aug;20(8):1408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
  • We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).
  • Interestingly, most of these cases had AML with AML1/ETO rearrangement.
  • To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).
  • The number of AML1/ETO+ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO- AML cells (2673 vs 522).
  • This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement.
  • We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Female. Flow Cytometry. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Receptors, Granulocyte Colony-Stimulating Factor / analysis. Receptors, Granulocyte Colony-Stimulating Factor / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791271.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


81. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL: Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res; 2006 Jun;30(6):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
  • Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported.
  • We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasms, Second Primary / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction. Time Factors. Transplantation, Homologous


82. Wang Y, Wu D, Sun A, Jin Z, Qiu H, Miao M, Tang X, Fu Z: Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol; 2008 Mar;87(2):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
  • The prognosis for patients with chronic myeloid leukemia (CML) in blast crisis (BC) remains dismal even with the availability of the BCR-ABL tyrosine kinase inhibitor imatinib, since it only offers short-term benefit in most cases.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) seems to be a viable option for BC-CML patients who attained remission.
  • After a median follow-up of 24 months (range 8-42), six out of the ten patients were alive in durable complete cytogenetic remission, one patient died in relapse 4 months after transplantation, the others died of severe acute graft-versus-host disease and associated infections.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blast Crisis / drug therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasm Recurrence, Local / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Cohort Studies. Female. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous


83. Sivendran S, Gruenstein S, Malone AK, Najfeld V: Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma. J Hematol Oncol; 2010;3:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.
  • Considering that ring chromosomes are rare in acute myelogenous leukemia (AML), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality.
  • Here we report a case of a ring chromosome 18 abnormality in a patient with newly diagnosed AML with monocytic differentiation.
  • The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic remission for 120 days post transplant.
  • Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of AML (likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Ring Chromosomes
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Treatment Outcome


84. Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH: Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leuk Res; 2006 Feb;30(2):204-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
  • For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m(2)/day, 24h i.v. infusion x 5), mitoxantrone (12 mg/m(2)/day x 3), and etoposide (150 mg/m(2)/day x 3).
  • Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Prospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 May;33(5):610-2 [18990445.001]
  • (PMID = 16055185.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


85. Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, Samuel S, Tsirigotis P, Gesundheit B, Slavin S, Shapira MY: Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant; 2006 Dec;12(12):1295-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of a mismatched allograft necessitates T cell depletion for prevention of uncontrolled graft-versus-host disease (GVHD), thus impairing a graft-versus-leukemia effect.
  • In the 6 patients receiving prophylactic DLI, complete remission was maintained in 5; however, 2 died from GVHD.
  • [MeSH-major] Graft Enhancement, Immunologic. Leukemia, Myeloid / surgery. Lymphocyte Transfusion. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child, Preschool. Feasibility Studies. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. HLA Antigens / immunology. Histocompatibility. Humans. Kaplan-Meier Estimate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukocyte Reduction Procedures. Lymphoma / surgery. Male. Middle Aged. Myelodysplastic Syndromes / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Remission Induction. Survival Analysis. Tissue Donors. Transplantation Conditioning. Tumor Burden

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162211.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


86. Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ: Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant; 2007 Oct;13(10):1160-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively analyzed outcomes among 307 consecutive patients who had recurrent or persistent acute leukemia (n = 244), chronic myelogenous leukemia in blast phase (CML; n = 28), or advanced myelodysplastic syndromes (MDS; n = 35) after allogeneic hematopoietic cell transplantation and who received at least 1 relapse-directed intervention: withdrawal of immunosuppression, chemotherapy, or donor lymphocyte infusion (DLI).
  • The overall remission rate was 30%.
  • Compared to early recurrence, intermediate recurrence and late recurrence were associated with increasing probabilities of remission (hazard ratios, 1.89 and 2.16; P = .05 and .02) and decreasing risks of overall mortality (hazard ratios, 0.73 and 0.33; P = .05 and <.0001).
  • Remission was associated with a median survival prolongation of 9.5 months.
  • Individual types or combinations of these nonrandomly assigned relapse-directed interventions were not associated with higher or lower probabilities of remission or survival.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889352.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / CA78902; United States / NIDDK NIH HHS / DK / DK064715; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


87. Satoh N, Takenouchi S, Hashimoto S, Fujiwara M, Koike T: Switching of donor cells after urgent second cord blood transplantation for suspected graft failure. Int J Hematol; 2007 Dec;86(5):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 44-year-old woman with acute myelogenous leukemia in partial remission received an unrelated CBT.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Delayed Graft Function / therapy. Graft Survival. Leukemia, Myeloid, Acute / therapy. Tissue Donors. Transplantation Conditioning
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / administration & dosage. Bone Marrow / metabolism. Bone Marrow / pathology. Donor Selection. Female. Ferritins / blood. Hematopoiesis. Humans. Macrophages / metabolism. Macrophages / pathology. Methylprednisolone / administration & dosage. Myeloablative Agonists / administration & dosage. Vascular Diseases / blood. Vascular Diseases / etiology. Vascular Diseases / pathology. Vascular Diseases / therapy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2006 Apr;37(8):787-8 [16501589.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5061-7 [12595310.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(7):368-76 [12171483.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):799-801 [12040480.001]
  • [Cites] Bone Marrow Transplant. 2006 Jul;38(2):83-93 [16751788.001]
  • [Cites] Int J Hematol. 2004 Dec;80(5):467-9 [15646662.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1915-9 [12738676.001]
  • [Cites] Int J Hematol. 2001 Feb;73(2):262-5 [11372742.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):36-41 [16371018.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):243-6 [11039676.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):535-44 [12829030.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):215-26 [9114593.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):999-1000 [15448661.001]
  • (PMID = 18192115.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Myeloablative Agonists; 9007-73-2 / Ferritins; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


88. Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J, Soiffer RJ: Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol; 2008 Oct;83(10):771-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
  • The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy.
  • Adults with de novo AML received daunorubicin and cytosine arabinoside induction therapy.
  • Patients achieving complete remission received high dose ara-C (HIDAC) for three courses followed by low dose rIL-2 (Amgen), administered by continuous infusion (450,000 U/m(2)/day) for 10 weeks with intermittent boluses (500,000/U/m(2) over 2 hr) given in weekly intervals starting on Week 4.
  • Mononuclear cells from patients receiving rIL-2 exhibited enhanced cytolytic activity in vitro against cryopreserved autologous leukemia cells.
  • This study supports further investigation of immunotherapy in the post-intensive chemotherapy setting in the management of patients with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Clinical Trials as Topic. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dose-Response Relationship, Drug. Fatigue / chemically induced. Feasibility Studies. Female. Fever / chemically induced. Follow-Up Studies. Humans. Interleukin-2 / administration & dosage. Interleukin-2 / genetics. Killer Cells, Natural / drug effects. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Remission Induction. Survival Analysis. T-Lymphocytes / drug effects. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18756547.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66996
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine
  •  go-up   go-down


89. Ohno R, Japan Adult Leukemia Study Group: Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Curr Hematol Malig Rep; 2006 Sep;1(3):180-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
  • The presence of the Philadelphia chromosome (Ph) is associated with a very poor prognosis in acute lymphoblastic leukemia (ALL).
  • Although hematologic complete remission (CR) is achieved in 50% to 80% of adult patients by intensive chemotherapy in multicenter studies, long-term outcome is dismal, with overall survival of approximately 10%.
  • Currently, allogeneic hematopoietic stem cell transplantation (allo-SCT) is thought to be the only curative therapeutic modality for this leukemia in adults, but the long-term survival rates are about 40% or less, far from satisfactory.
  • Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adult. Benzamides. Clinical Trials as Topic / statistics & numerical data. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Multicenter Studies as Topic / statistics & numerical data. Piperazines / administration & dosage. Prednisolone / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage. Remission Induction. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):79-84 [14979483.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):635-7 [3027581.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Science. 1988 Feb 12;239(4841 Pt 1):775-7 [3422516.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):623-32 [12692601.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Int J Hematol. 1998 Dec;68(4):421-9 [9885441.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3507-12 [15315963.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2636-42 [14669283.001]
  • [Cites] Cell. 1987 Oct 9;51(1):33-40 [2820585.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):279-89 [9846012.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1811-22 [11753600.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3691-8 [9345054.001]
  • [Cites] Blood Cells Mol Dis. 1997 Dec;23(3):380-94 [9446752.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3948-54 [16105974.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Blood. 2003 Jan 15;101(2):473-5 [12393385.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • (PMID = 20425349.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 2.7.10.2 / Fusion Proteins, bcr-abl; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CVAD protocol
  • [Number-of-references] 37
  •  go-up   go-down


90. Thomas X: The role of timed sequential chemotherapy in adult acute myelogenous leukemia. Curr Hematol Malig Rep; 2008 Apr;3(2):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of timed sequential chemotherapy in adult acute myelogenous leukemia.
  • Consecutive trials of timed sequential chemotherapy (TSC) have been conducted in adults with acute myelogenous leukemia.
  • Achieving complete remission is essential for prolonged disease-free survival and may affect long-term outcome.
  • TSC has led to higher rates of complete remission and has improved long-term outcomes.
  • This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Cell Cycle / drug effects. Clinical Trials as Topic. Drug Administration Schedule. Humans


91. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M: Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant; 2006 Sep;38(6):421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen patients with acute leukemia (n=9), chronic myelogenous leukemia (n=2), multiple myeloma (n=2) and lymphoma (n=2) were treated; 60% had relapsed disease at transplantation.
  • Two patients are alive and disease free; 4-year actuarial survival is 33 versus 0% for patients transplanted in remission versus in relapse.
  • [MeSH-minor] Adult. Antilymphocyte Serum / administration & dosage. Antilymphocyte Serum / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Graft Rejection / mortality. Graft Survival. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Myeloablative Agonists / administration & dosage. Myeloablative Agonists / adverse effects. Recurrence. Risk Factors. Tacrolimus / administration & dosage. Tacrolimus / adverse effects. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 7 August 2006.
  • (PMID = 16892072.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res; 2008 Mar 1;14(5):1446-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
  • PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
  • Nine patients had relapsed AML (ages, 18-59 years, n = 4 and > or = 60 years, n = 5).
  • There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).
  • Overall, 19 patients (61%) achieved complete remission (CR) and three had CR with incomplete platelet recovery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Boronic Acids / administration & dosage. Bortezomib. Cohort Studies. Cytarabine / administration & dosage. Female. Gene Expression Profiling. Humans. Idarubicin / administration & dosage. M